241 – 250 of 317
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
(
- Contribution to journal › Article
-
Mark
The economics of haemophilia prophylaxis; governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium.
(
- Contribution to journal › Article
- 2006
-
Mark
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
(
- Contribution to journal › Article
-
Mark
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the international prophylaxis study group
(
- Contribution to journal › Article
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
(
- Contribution to journal › Article
-
Mark
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(
- Contribution to journal › Article
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
(
- Contribution to journal › Article